New human myelodysplastic cell line, TER-3: G-CSF specific downregulation of Ca2+/calmodulin-dependent protein kinase IV.
We have established a new hematopoietic cell line from a patient with myelodysplastic syndrome (MDS), which was refractory anemia with excess blasts (RAEB). This cell line, designated TER-3, depends on several cytokines for long-term survival and growth, and requires interleukin-3 (IL-3) for continuous growth. Cytochemical analysis revealed that TER-3 cells are weakly dianisidine positive and nonspecific esterase positive, but peroxidase negative. The surface marker profile shows that the TER-3 cells are strongly positive for myeloid, lymphoid, and megakaryocytic antigens such as CD15, CD19, and CD61, and negative for some common multilineage antigens such as CD13, CD33, and CD34. Thus, this cell line has a multilineage phenotype, suggesting that the transformation event occurred in multipotent stem cells. Dianisidine- and nonspecific esterase-positive TER-3 cells increase with granulocyte-colony stimulating factor (G-CSF) rather than with IL-3. These results suggest that the cell line is useful for understanding the mechanism underlying G-CSF-associated hematopoietic cell differentiation and activation in the patient with MDS.
Mishima
Yuji
Y
Biochemical Research Laboratory, Morinaga Milk Industry Co., Ltd., Zama, Kanagawa, Japan.
Terui
Yasuhito
Y
Mishima
Yuko
Y
Katsuyama
Misa
M
Mori
Masaki
M
Tomizuka
Hiroshi
H
Takizawa
Toshiyuki
T
Miyazato
Akira
A
Ueda
Masuzu
M
Yamada
Muneo
M
Hayasawa
Hirotoshi
H
Mizunuma
Nobuyuki
N
Ishizaka
Yukihito
Y
Ikeda
Kazuma
K
Kato
Takashi
T
Ozawa
Keiya
K
Hatake
Kiyohiko
K
D000954:Antigens, Surface / Q000378:metabolism; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D054734:Calcium-Calmodulin-Dependent Protein Kinase Type 4; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D018929:Cell Culture Techniques; D002454:Cell Differentiation / Q000187:drug effects* / Q000502:physiology; D002455:Cell Division / Q000187:drug effects* / Q000502:physiology; D002460:Cell Line / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D048429:Cell Size / Q000502:physiology; D004247:DNA / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects* / Q000502:physiology; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007377:Interleukin-3 / Q000378:metabolism / Q000494:pharmacology; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism
D000954:Antigens, Surface; D007377:Interleukin-3; D012333:RNA, Messenger; D016179:Granulocyte Colony-Stimulating Factor; D004247:DNA; C517683:CAMK4 protein, human; D054734:Calcium-Calmodulin-Dependent Protein Kinase Type 4; D017871:Calcium-Calmodulin-Dependent Protein Kinases